JP2948271B2 - 新規の多孔性製剤及びその製造方法 - Google Patents

新規の多孔性製剤及びその製造方法

Info

Publication number
JP2948271B2
JP2948271B2 JP2131437A JP13143790A JP2948271B2 JP 2948271 B2 JP2948271 B2 JP 2948271B2 JP 2131437 A JP2131437 A JP 2131437A JP 13143790 A JP13143790 A JP 13143790A JP 2948271 B2 JP2948271 B2 JP 2948271B2
Authority
JP
Japan
Prior art keywords
paste
cyclodextrin
water
optionally
lyophilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2131437A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0356412A (ja
Inventor
フレデリク・クールテイユ
マガリ・バヌーブ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ROONU PUURAN SANTE
Original Assignee
ROONU PUURAN SANTE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ROONU PUURAN SANTE filed Critical ROONU PUURAN SANTE
Publication of JPH0356412A publication Critical patent/JPH0356412A/ja
Application granted granted Critical
Publication of JP2948271B2 publication Critical patent/JP2948271B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Materials For Medical Uses (AREA)
  • Filtering Materials (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2131437A 1989-05-24 1990-05-23 新規の多孔性製剤及びその製造方法 Expired - Lifetime JP2948271B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8906781A FR2647343B1 (fr) 1989-05-24 1989-05-24 Nouvelle forme pharmaceutique poreuse et sa preparation
FR8906781 1989-05-24

Publications (2)

Publication Number Publication Date
JPH0356412A JPH0356412A (ja) 1991-03-12
JP2948271B2 true JP2948271B2 (ja) 1999-09-13

Family

ID=9381955

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2131437A Expired - Lifetime JP2948271B2 (ja) 1989-05-24 1990-05-23 新規の多孔性製剤及びその製造方法

Country Status (24)

Country Link
US (1) US5244881A (d)
EP (2) EP0399902B1 (d)
JP (1) JP2948271B2 (d)
KR (1) KR0163423B1 (d)
AT (2) ATE98867T1 (d)
AU (2) AU623779B2 (d)
CA (2) CA2017360A1 (d)
DD (1) DD297915A5 (d)
DE (2) DE69000641T2 (d)
DK (2) DK0399903T3 (d)
ES (2) ES2062437T3 (d)
FI (1) FI103712B1 (d)
FR (1) FR2647343B1 (d)
GR (1) GR3006655T3 (d)
IE (2) IE64370B1 (d)
IL (2) IL94459A (d)
NO (1) NO180517C (d)
NZ (2) NZ233766A (d)
PL (1) PL285327A1 (d)
PT (2) PT94138B (d)
TW (1) TW257672B (d)
WO (1) WO1990014089A1 (d)
YU (1) YU100790A (d)
ZA (2) ZA903895B (d)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69231457T2 (de) * 1991-06-21 2001-05-23 Takeda Chemical Industries Ltd Zyklodextrin-Zusammensetzung enthaltend Fumagillol-Derivate
NZ246091A (en) 1991-12-24 1995-08-28 Yamanouchi Pharma Co Ltd Intrabuccally disintegrating preparation containing an active ingredient, agar, and lactose and/or mannitol
GB9318880D0 (en) * 1993-09-11 1993-10-27 Smithkline Beecham Plc Pharmaceutical composition
JPH10500982A (ja) * 1994-05-27 1998-01-27 ファーマーク、ネダーランド、ベスローテン、フェンノートシャップ 医薬組成物
CA2281473C (en) * 1997-02-20 2007-01-16 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
BE1011251A3 (fr) * 1997-07-03 1999-06-01 Ucb Sa Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
TW527195B (en) 1997-10-09 2003-04-11 Ssp Co Ltd Fast-soluble solid pharmaceutical combinations
WO1999039694A2 (en) * 1998-02-05 1999-08-12 Novartis Ag Compositions containing organic compounds
IT1304190B1 (it) * 1998-12-18 2001-03-08 Euphar Group Srl Clatrati di deidroepiandrosterone e relative composizionifarmaceutiche
US6287603B1 (en) * 1999-09-16 2001-09-11 Nestec S.A. Cyclodextrin flavor delivery systems
US20050038039A1 (en) 2002-01-15 2005-02-17 Domenico Fanara Formulations
AU2003215396B2 (en) 2002-02-25 2010-04-08 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
DE10239531A1 (de) * 2002-08-23 2004-03-04 Gulbins, Erich, Prof. Dr. Prophylaxe und Therapie von Infektionserkrankungen
DE10248314A1 (de) * 2002-10-16 2004-04-29 Dr. Suwelack Skin & Health Care Ag Verwendung von Formkörpern zur äußeren Anwendung
FR2876910B1 (fr) * 2004-10-21 2007-04-13 Pierre Fabre Medicament Sa Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction
UA95903C2 (ru) 2005-02-24 2011-09-26 Дифьюжен Фармасьютикалз Ллк Транс-каротиноиды, их синтез, лекарственная форма и применение
DE102005041860A1 (de) * 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
KR101570131B1 (ko) 2007-04-13 2015-11-18 디퓨젼 파마슈티컬즈 엘엘씨 양극성 트랜스 카로티노이드의 말초혈관질환 치료와 예방을 위한 용도
JP2009091309A (ja) * 2007-10-10 2009-04-30 Japan Organo Co Ltd バコパモニエラエキスを含有する組成物およびその製造方法ならびに飲食品
JP2011502125A (ja) 2007-10-31 2011-01-20 ディフュージョン・ファーマシューティカルズ・エルエルシー 小分子拡散を促進する新しい種類の治療法
ES2564056T3 (es) * 2008-09-05 2016-03-17 Johnson & Johnson Consumer Inc. Método para hacer pastillas de cetirizina
CN108464976A (zh) 2009-06-22 2018-08-31 扩散药品有限公司 扩散促进化合物及其单独或与溶栓药一起的应用
WO2011152869A1 (en) 2010-06-02 2011-12-08 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
JP5890951B2 (ja) * 2010-09-13 2016-03-22 ベヴ−アールエックス、インク． 不快味マスキング剤を有する水性薬物送達システム
RU2609198C1 (ru) * 2016-01-25 2017-01-30 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма имипрамина немедленного высвобождения и способ ее получения
CN115089569A (zh) 2016-03-24 2022-09-23 扩散药品有限公司 双极性反式类胡萝卜素连同化疗和放射治疗在治疗癌症中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5443570B2 (d) * 1972-10-27 1979-12-20
IE45770B1 (en) * 1976-10-06 1982-11-17 Wyeth John & Brother Ltd Pharmaceutical dosage forms
US4165382A (en) * 1977-10-17 1979-08-21 Jose Pozuelo Method of pharmacologically treating schizophrenia with alpha-methyl-para-tyrosine
US4349472A (en) * 1979-04-27 1982-09-14 Schering Corporation (S)-8(1-Adamantanecarbonyloxy)-7-chloro-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
US4284555A (en) * 1979-04-27 1981-08-18 Schering Corporation 7-Chloro-8(substituted amino carbonyloxy)-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
US4477378A (en) * 1980-02-05 1984-10-16 Schering Corp. Esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
JPS61267555A (ja) * 1984-11-27 1986-11-27 Dainippon Pharmaceut Co Ltd キノリン誘導体及びそれを有効成分とする抗潰瘍剤
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition

Also Published As

Publication number Publication date
DE69005359D1 (de) 1994-02-03
ATE98867T1 (de) 1994-01-15
FI902553A0 (fi) 1990-05-23
WO1990014089A1 (fr) 1990-11-29
AU5743390A (en) 1990-12-18
FR2647343B1 (fr) 1994-05-06
IL94459A0 (en) 1991-03-10
NO902280L (no) 1990-11-26
NO902280D0 (no) 1990-05-23
PT94138B (pt) 1996-12-31
US5244881A (en) 1993-09-14
AU631888B2 (en) 1992-12-10
DD297915A5 (de) 1992-01-30
NZ233784A (en) 1993-04-28
DE69000641T2 (de) 1993-06-09
DK0399903T3 (da) 1993-02-08
IE64370B1 (en) 1995-07-26
EP0399902A1 (fr) 1990-11-28
FI103712B (fi) 1999-08-31
CA2017360A1 (fr) 1990-11-24
PL285327A1 (en) 1991-02-11
ES2062437T3 (es) 1994-12-16
DE69005359T2 (de) 1994-05-05
EP0399902B1 (fr) 1993-12-22
EP0399903A1 (fr) 1990-11-28
ZA903978B (en) 1991-03-27
NO180517C (no) 1997-05-07
IL94459A (en) 1995-01-24
IL94460A0 (en) 1991-03-10
DK0399902T3 (da) 1994-02-14
PT94138A (pt) 1991-01-08
NZ233766A (en) 1991-08-27
CA2017355A1 (fr) 1990-11-24
ATE83663T1 (de) 1993-01-15
DE69000641D1 (de) 1993-02-04
JPH0356412A (ja) 1991-03-12
IE63317B1 (en) 1995-04-05
NO180517B (no) 1997-01-27
ES2054289T3 (es) 1994-08-01
PT94139B (pt) 1996-12-31
IE901821L (en) 1990-11-24
FR2647343A1 (fr) 1990-11-30
IE901862L (en) 1990-11-24
PT94139A (pt) 1991-01-08
AU623779B2 (en) 1992-05-21
AU5582890A (en) 1991-01-10
GR3006655T3 (d) 1993-06-30
KR0163423B1 (ko) 1998-12-01
KR900017570A (ko) 1990-12-19
EP0399903B1 (fr) 1992-12-23
FI103712B1 (fi) 1999-08-31
TW257672B (d) 1995-09-21
YU100790A (en) 1992-05-28
ZA903895B (en) 1991-03-27

Similar Documents

Publication Publication Date Title
JP2948271B2 (ja) 新規の多孔性製剤及びその製造方法
US5206025A (en) Porous pharmaceutical form and its preparation
KR890002949B1 (ko) 경구용 약제 조성물의 제조방법
RU2242968C2 (ru) Быстродиспергирующаяся лекарственная форма, не содержащая желатин
JP4336021B2 (ja) 口腔内崩壊型錠剤およびその製造法
US5505959A (en) Pharmaceutical composition in gel form in a dispensing package
KR101590115B1 (ko) 약학 조성물
CA2543324C (en) Rapidly disintegrating films for delivery of pharmaceutical or cosmetic agents
JP2000504028A (ja) 口内薬剤輸送系
WO1999018936A1 (en) Quickly soluble solid preparations
JP6820116B2 (ja) レボセチリジンを含む医薬組成物
CN115212179B (zh) 一种3d打印凝胶基质及其制备方法和其应用
CN108778342B (zh) 基于环糊精和三氯蔗糖的高生物利用度口腔粘膜药物制剂
JPH11199517A (ja) 口腔内速崩壊性錠剤
CN110325178B (zh) 改善含量均一性的制剂的制造方法
JP2511577B2 (ja) アルギン酸プロピレングリコ―ルエステルからなる徐放性製剤
JP2002308760A (ja) 圧縮成型用組成物及びその利用
JPH035438A (ja) フルルビプロフェン包接化合物およびこの包接化合物を用いる消炎鎮痛剤
JP2018500278A (ja) 外部粘膜に適用する剤形物品
JP4634589B2 (ja) 食品又は医薬品易服用化剤
JP2002154988A (ja) 口腔内崩壊錠剤およびその製造方法
JP2008133294A (ja) 口腔内崩壊型錠剤
CA3256935A1 (en) PAN-RAF KINASE INHIBITOR ORAL LIQUID SUSPENSION
TW201306876A (zh) 乾粉漿組合物
MXPA01007569A (en) Fast dispersing dosage forms free of gelatin

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20070702

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080702

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090702

Year of fee payment: 10

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090702

Year of fee payment: 10

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090702

Year of fee payment: 10

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100702

Year of fee payment: 11

EXPY Cancellation because of completion of term